医学
内科学
肿瘤科
淋巴血管侵犯
列线图
比例危险模型
新辅助治疗
肺癌
阶段(地层学)
化疗
回顾性队列研究
风险因素
T级
原发性肿瘤
总体生存率
癌症
生存分析
根治性手术
递归分区
完全响应
临床试验
肺
预测值
外科
癌
全肺切除术
切断
存活率
作者
Ruihe Liu,Shenhua Liang,Jiayuan Tian,Yitao Yang,Xingyu Luo,Guowei Ma
标识
DOI:10.1016/j.ctarc.2026.101462
摘要
BACKGROUND: Recent clinical trials have identified the percentage of residual viable tumor (%RVT) following neoadjuvant immunochemotherapy as a prognostic risk factor for patients with non-small cell lung cancer (NSCLC). This study aimed to identify the significance of %RVT concerning the patterns of postoperative recurrence. METHODS: This retrospective study involved 339 patients diagnosed with NSCLC who underwent neoadjuvant immunochemotherapy followed by radical surgical intervention. The optimal cutoff value of %RVT was identified as a continuous covariate for recurrence-free survival (RFS) using the rolr R package. RESULTS: In our cohort, the estimated optimal cutoffs for %RVT were identified as 5% and 30%. Patients with >30% RVT exhibited significantly worse RFS compared to those with 6-30% RVT (P = 0.026) and those with ≤5% RVT (P < 0.001). The overall recurrence rate (≤5% RVT, 12.2%; 6-30% RVT, 29.4%; >30% RVT, 37.1%; P < 0.001) and distant recurrence rate (≤5% RVT, 2.7%; 6-30% RVT, 16.7%; >30% RVT, 24.7%; P < 0.001) increased progressively with advancing %RVT. Cox regression analyses revealed that %RVT, visceral pleural infiltration, lymphovascular infiltration, and pN stage were independent risk factors for RFS. Based on these identified factors, a nomogram model was subsequently developed, yielding a corrected C-index of 0.701 through bootstrap analysis. CONCLUSIONS: We identified %RVT in post-treatment tumor lesions as a significant risk factor for the recurrence of NSCLC following neoadjuvant immunochemotherapy and surgery, with optimal cutoffs established at 5% and 30%. Furthermore, an increase in %RVT may have a more pronounced effect on distant recurrence.
科研通智能强力驱动
Strongly Powered by AbleSci AI